Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
Tom Langenaeken, Resident Cardiac Surgery at Catharina Ziekenhuis, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Vessels, Thrombosis & Haemostasis, adding:
“Our paper on Factor XI inhibition with gruticibart (AB023) for mechanical heart valve thrombosis is now published in Blood Vessels, Thrombosis & Haemostasis.
In a porcine pulmonary valve model, gruticibart achieved 100% valve patency without bleeding events at three months despite IV administration only once every 2 weeks.
A result we believe makes a compelling case for FXI as the target antithrombotic strategy in mechanical valve recipients.
This pilot study is the foundation for a larger follow-up series, which we are pleased to pursue with support from the Foundation for Cardiac Surgery.”
Title: Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model
Authors: Tom Langenaeken, Lennart Vanglabeke, Manon Van Hecke, Pieter De Meester, Tom Verbelen, Peter Verbrugghe, Filip Rega, Christina U Lorentz, Erik I Tucker, Bart Meuris
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 22, 2026, 19:02Blocking Histone-Induced Platelet-Erythrocyte Interactions With Polyanions – Platelets Journal
-
Sep 22, 2026, 18:49Abdul Rahman Hamad: Early Action for Better Outcomes in Deep Vein Thrombosis
-
Sep 22, 2026, 18:37Carmine Siniscalchi: Age-Adjusted D-Dimer Cutoffs in DVT Diagnosis
-
Sep 22, 2026, 18:37Stefano Romeo: The Cardiovascular Patient Journey is Still Full of Gaps
-
Sep 22, 2026, 18:11Bharath Kumar V.։ Advancing Safer Anticoagulation for Cancer-Associated Thrombosis
-
Sep 22, 2026, 18:10Fatima Zahra: ASH Released New Guidelines on the Diagnosis of Iron Deficiency
-
Sep 22, 2026, 17:49Nirav Dhanesha: Targeting FXI for Safer Anticoagulation
-
Sep 22, 2026, 17:17Eric Lambert: Intravascular Imaging and the Future of Precision PCI
-
Sep 22, 2026, 16:45Claudiu Stoicescu: Are We Starting Cardiovascular Risk Assessment Too Late?